Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arena Pharmaceutical (ARNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 424,667
  • Shares Outstanding, K 307,730
  • Annual Sales, $ 123,980 K
  • Annual Income, $ -22,520 K
  • 36-Month Beta -0.92
  • Price/Sales 3.45
  • Price/Cash Flow 0.00
  • Price/Book 8.38

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.20 +15.00%
on 04/18/17
1.50 -8.00%
on 03/28/17
-0.11 (-7.38%)
since 03/27/17
3-Month
1.20 +15.00%
on 04/18/17
1.70 -18.82%
on 03/15/17
-0.10 (-6.76%)
since 01/27/17
52-Week
1.20 +15.00%
on 04/18/17
2.16 -36.11%
on 06/09/16
-0.41 (-22.91%)
since 04/27/16

Most Recent Stories

More News
Arena Pharma (ARNA) Down After Underwritten Public Offering

Arena Pharmaceuticals, Inc.'s (ARNA) shares dropped more than 13% on Apr 18, after the company announced that it will be raising funds through an underwritten public offering.

HSKA : 105.22 (-2.69%)
AGLE : 6.96 (+0.14%)
GALE : 0.62 (-1.59%)
ARNA : 1.38 (-0.72%)
Biotech Industry Outperforming Major Indexes in 2017: Today's Research Reports on Arena Pharmaceuticals and Cytokinetics

NEW YORK, NY / ACCESSWIRE / April 19, 2017 / The Biotech Industry has continued to outperform the major indexes in 2017. This comes as a welcome sign to biotech investors after a tumultuous 2016. The iShares...

CYTK : 17.00 (+0.59%)
ARNA : 1.38 (-0.72%)
XBI : 71.19 (+0.91%)
Why Is Arena Pharmaceuticals (ARNA) Down 11.3% Since the Last Earnings Report?

Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ARNA : 1.38 (-0.72%)
Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Arena...

ARNA : 1.38 (-0.72%)
Arena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at Experimental Biology

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced three data presentations on...

ARNA : 1.38 (-0.72%)
Biotech Stocks on Investors' Radar -- Halozyme Therapeutics, Cara Therapeutics, PDL BioPharma, and Arena Pharma

On Wednesday, benchmark US indices were in bearish colors as the NASDAQ Composite closed the trading session down 0.52%; the Dow Jones Industrial Average edged 0.29% lower; and the S&P 500 was down 0.38%....

CARA : 15.96 (unch)
PDLI : 2.28 (-1.30%)
ARNA : 1.38 (-0.72%)
HALO : 13.99 (+0.79%)
New Strong Sell Stocks for April 6th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

LIQT : 0.38 (unch)
CSIQ : 13.68 (-2.08%)
FRTA : 19.54 (+2.30%)
CNFR : 7.90 (unch)
ARNA : 1.38 (-0.72%)
Today's Research Reports on Biotech Stocks to Watch: Arena Pharmaceuticals and Immunomedics

NEW YORK, NY / ACCESSWIRE / March 28, 2017 / The market is currently shaping up for an interesting week, with the Trumpcare bill still casting its shadow on the industry. The share prices of the industry's...

ARNA : 1.38 (-0.72%)
IMMU : 5.60 (+1.45%)
Arena Pharmaceuticals Appoints Dr. Preston Klassen, M.D., M.H.S. as Executive Vice President, Research and Development and Chief Medical Officer

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, today announced the appointment of Dr. Preston...

ARNA : 1.38 (-0.72%)
Arena Pharmaceuticals (ARNA) Posts Q4 Earnings, Revenues Up

Arena Pharmaceuticals, Inc. (ARNA) reported earnings of 16 cents per share in the fourth quarter of 2016, as against the year-ago loss of 13 cents and the Zacks Consensus Estimate of a loss of 9 cents....

ABCO : 49.10 (+5.48%)
BCRX : 6.41 (+1.26%)
ARNA : 1.38 (-0.72%)
ADUS : 33.85 (+1.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their...

See More

Support & Resistance

2nd Resistance Point 1.42
1st Resistance Point 1.40
Last Price 1.38
1st Support Level 1.37
2nd Support Level 1.36

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.